Form 8-K - Current report:
SEC Accession No. 0001171843-25-004808
Filing Date
2025-07-30
Accepted
2025-07-30 07:06:05
Documents
14
Period of Report
2025-07-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_073025.htm   iXBRL 8-K 15645
2 PRESS RELEASE exh_991.htm EX-99.1 566821
  Complete submission text file 0001171843-25-004808.txt   825821

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20250101.xsd EX-101.SCH 3402
4 XBRL DEFINITION FILE gnw-20250101_def.xml EX-101.DEF 26066
5 XBRL LABEL FILE gnw-20250101_lab.xml EX-101.LAB 35956
6 XBRL PRESENTATION FILE gnw-20250101_pre.xml EX-101.PRE 24702
17 EXTRACTED XBRL INSTANCE DOCUMENT f8k_073025_htm.xml XML 3231
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV Israel
Business Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV Israel 972 (3) 914-8213
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16174 | Film No.: 251163934
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)